Skip to Main Content
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
book

Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

by Honghui Zhou, Diane R. Mould
March 2019
Intermediate to advanced content levelIntermediate to advanced
496 pages
15h
English
Wiley
Content preview from Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

7Modeling Approaches to Characterize Target‐Mediated Pharmacokinetics and Pharmacodynamics for Therapeutic Proteins

Leonid Gibiansky and Ekaterina Gibiansky

QuantPharm LLC, North Potomac, MD, USA

7.1 Introduction

Many therapeutic proteins are designed to be highly specific and act by binding to a specific target. Binding to the target may strongly influence or even dominate pharmacokinetic (PK) and pharmacodynamic (PD) properties of these drugs, especially at low concentrations. Therapeutic proteins are cleared by two distinct pathways: linear (non‐target) and target mediated. Catabolism (for large molecules, e.g. whole immunoglobulin G (IgG) antibodies) and renal filtration (for smaller molecules, e.g. antibody fragments) are mostly responsible for the linear clearance. These mechanisms are more important at high concentrations when the nonlinear target‐mediated elimination pathway is saturated. Target‐mediated clearance eliminates drug–target complex that is created by binding of the drug to its target. This clearance mechanism commonly involves internalization of cell surface receptors (if the target is on a cell surface) followed by endocytosis, or catabolism (for soluble targets). Target‐mediated clearance may dominate elimination at low concentrations, resulting in faster than linear clearance of the drug.

The term “target‐mediated drug disposition” (TMDD) was first introduced by Levy [1]. A TMDD model, that is, a mathematical description of the TMDD processes, has been proposed ...

Become an O’Reilly member and get unlimited access to this title plus top books and audiobooks from O’Reilly and nearly 200 top publishers, thousands of courses curated by job role, 150+ live events each month,
and much more.
Start your free trial

You might also like

Applied Computing in Medicine and Health

Applied Computing in Medicine and Health

Dhiya Al-Jumeily, Abir Hussain, Conor Mallucci, Carol Oliver
Informatics for Health Professionals

Informatics for Health Professionals

Kathleen Mastrian, Dee McGonigle
Nanostructures for Novel Therapy

Nanostructures for Novel Therapy

Denisa Ficai, Alexandru Mihai Grumezescu

Publisher Resources

ISBN: 9781119289197Purchase book